

SUBJECT: **CONSENT AGENDA: REFLECTING BOARD-APPROVED CHANGES TO ELIGIBILITY AND TRANSITION POLICY**

Agenda item: 02i

Category: For Decision

Section A : Introduction

- In November 2017, the Gavi Alliance Board “*approved the extension of the grace period for new vaccine introduction during the accelerated transition phase (Phase 2) from one year to the full five years, if vaccine introductions during accelerated transition effectively contribute to strengthening routine immunisation and increasing coverage and equity.*” (Decision 12b,[a])
- To reflect this decision, the Gavi Alliance Policy and Programme Committee recommends that the Board approve modifications to paragraphs 7.6 and 7.7 of the Eligibility and Transition Policy.

Section B : Actions requested of the Board

Further to the decision of the Gavi Alliance Board in November 2017 to extend the grace period, the Gavi Alliance Programme and Policy Committee recommends to the Gavi Alliance Board that it:

- **Approve** the following modifications to Gavi’s Eligibility and Transition Policy:

7.6 Countries are eligible to apply for new vaccine support during the five years of Phase 2, provided that vaccine introductions during this phase effectively contribute to strengthening routine immunisation and increasing coverage and equity.

~~7.6.~~ 7.7 Countries that surpass the Eligibility Threshold have one year to apply for new HSS (i.e. for a country that has not received any HSS support from Gavi yet) ~~and vaccine support~~, from January 1 of the year after surpassing the Eligibility Threshold (a grace year). However, new HSS support is restricted to those countries with Penta3 coverage below 90%.

~~7.7. From the second year in Phase 2, countries cannot submit new applications or resubmit previously rejected applications for any of Gavi’s funding windows.~~